Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AES Corp (AES) vs Cassava Sciences Inc (FLNA) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

AES Corp vs Cassava Sciences Inc — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: AES Corp is far larger — about 219.7× Cassava Sciences Inc's market cap, and AES Corp pays a 4.79% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

AESFLNA
Market Cap
$10.49B$47.75M
Sector
UtilitiesHealth
52-Week High
$17.28$4.64
52-Week Low
$12.51$0.87
Enterprise Value
$40.75B-$34.93M
Dividend Yield
4.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AES Corp

AES trades at $14.73, unchanged on the day, with a bullish technical signal from moving averages and a pending acquisition by Global Infrastructure Partners and EQT at $15 per share. The company reported revenue of $12.23B in 2025, with a net income margin of 7.43%, and has beaten earnings estimates in two of the last three quarters. Valuation ratios appear attractive with a P/E of 5.51 and P/S of 0.81, while cash flow from operations improved to $4.31B in 2025.

The outlook is dominated by the acquisition, offering a capped upside to $15. Strong profitability metrics like a 45.05% ROE and a 4.8% dividend yield provide support, but risks include shareholder litigation and regulatory scrutiny over the deal. Analyst sentiment is mixed with 42.86% buy ratings, reflecting uncertainty until transaction closure.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About AES Corp

AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.

Read more on AES

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA